Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Dimerix Limited ( (AU:DXB) ).
Dimerix Limited announced the successful completion of a data analysis by the PARASOL collaboration, which supports the use of proteinuria endpoints in their ACTION3 study for potential marketing approval in the US. The analysis observed a potential relationship between proteinuria at 12 months and the risk of kidney failure, which will be discussed with the FDA for possible accelerated approval pathways. This development could significantly impact Dimerix’s operations and industry positioning by potentially expediting the approval process for their kidney disease treatment, thereby benefiting stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a biopharmaceutical company focused on developing innovative therapies for areas with unmet medical needs, particularly in the field of kidney disease. The company is headquartered in Fitzroy, Victoria, Australia, and is engaged in advancing its Phase 3 clinical asset targeting kidney disease.
Average Trading Volume: 1,438,325
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$315.1M
Learn more about DXB stock on TipRanks’ Stock Analysis page.